Eyegate Pharmaceuticals, Inc. (EYEG) Hits New 1-Year Low at $0.98
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG)’s share price reached a new 52-week low on Thursday . The stock traded as low as $0.98 and last traded at $0.98, with a volume of 552,940 shares trading hands. The stock had previously closed at $1.12.
Several equities analysts have recently weighed in on the stock. HC Wainwright set a $6.00 target price on shares of Eyegate Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday. Noble Financial reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a report on Friday, May 19th.
The company’s market capitalization is $17.03 million. The company has a 50 day moving average of $1.32 and a 200 day moving average of $1.86.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last released its earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.39) EPS for the quarter, meeting analysts’ consensus estimates of ($0.39). Eyegate Pharmaceuticals had a negative return on equity of 840.69% and a negative net margin of 1,737.29%. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.22 million. On average, equities research analysts expect that Eyegate Pharmaceuticals, Inc. will post ($1.24) earnings per share for the current year.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.